

Remarks

Applicant's Attorney hereby states that the change made in the sequence listing, does not include new matter. Support for this amendment is found, inter alia, in Figure 1. Applicant's undersigned attorney has amended the specification only to direct the entry of this corrected Sequence Listing at the end of the application.

On accordance with 37 C.F.R. § 1.821(g), this submission includes no new matter.

In accordance with 37 C.F.R. § 1.825(b), the paper copy of the Sequence Listing and the computer readable copy of the Sequence Listing submitted herewith are the same.

In the initial sequence listing filed September 14, 2001, SEQ ID NO. 1 has been amended. Nucleotides from 699 to 776 were inadvertantly left out. The corrected SEQ ID NO. 1 is submitted herewith.

New SEQ ID NO. 3 represents the elected species in which a leucine is substituted for Isoleucine.

New SEQ ID NO. 4 represents the sequence shown in claim 1.

It is respectfully believed this application is now in condition for allowance. Early notice to this effect is earnestly solicited.

Summary


Applicants submit herewith both paper and computer copies of the Sequence Listing.
No new matter has been added to the application by way of the amendment presented herein.

Applicants respectfully request that the Sequence Listing submitted herewith be introduced into the captioned application.

It is respectfully believed that this application is now in condition for examination.
Early notice to this effect is respectfully requested.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Michele A. Cimbala
Attorney for Applicant
Registration No. 33,851

Date: May 28, 2002

1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
(202) 371-2600